Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · IEX Real-Time Price · USD
2.390
-0.030 (-1.24%)
At close: Mar 28, 2024, 4:00 PM
2.380
-0.010 (-0.42%)
After-hours: Mar 28, 2024, 7:54 PM EDT
Coherus BioSciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Coherus BioSciences stock have an average target of 9.20, with a low estimate of 7.00 and a high estimate of 11. The average target predicts an increase of 284.94% from the current stock price of 2.39.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CHRS stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $11 | Strong Buy | Maintains | $13 → $11 | +360.25% | Mar 20, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +443.93% | Mar 14, 2024 |
Baird | Baird | Buy Maintains $11 → $9 | Buy | Maintains | $11 → $9 | +276.57% | Jan 23, 2024 |
Truist Securities | Truist Securities | Strong Buy Maintains $12 → $8 | Strong Buy | Maintains | $12 → $8 | +234.73% | Jan 23, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +443.93% | Dec 27, 2023 |
Financial Forecast
Revenue This Year
353.86M
from 257.24M
Increased by 37.56%
Revenue Next Year
444.46M
from 353.86M
Increased by 25.60%
EPS This Year
-0.25
from -2.53
EPS Next Year
0.02
from -0.25
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 431.6M | 669.5M | 945.0M | 1.1B | 1.2B |
Avg | 353.9M | 444.5M | 751.2M | 818.0M | 840.3M |
Low | 237.2M | 245.0M | 585.5M | 619.2M | 630.3M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 67.8% | 89.2% | 112.6% | 47.5% | 41.2% |
Avg | 37.6% | 25.6% | 69.0% | 8.9% | 2.7% |
Low | -7.8% | -30.8% | 31.7% | -17.6% | -22.9% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 0.38 | 0.48 | 1.54 | 2.17 | 2.34 |
Avg | -0.25 | 0.02 | 1.12 | 1.82 | 1.62 |
Low | -0.75 | -0.57 | 0.71 | 1.46 | 0.92 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | 9,855.5% | 94.6% | 29.0% |
Avg | - | - | 7,103.9% | 62.6% | -11.0% |
Low | - | - | 4,451.1% | 30.7% | -49.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.